Renalyx Health Systems Launches AI-Enabled Smart Hemodialysis Machine

Renalyx Health Systems

Pune: In a major stride towards transforming kidney care in India and globally, Renalyx Health Systems has launched the RENALYX – RxT 21, the world’s first fully indigenous AI-based smart hemodialysis machine.

This advanced system combines cloud technology, remote monitoring, and AI-driven clinical insights, enabling high-quality, affordable dialysis – especially in underserved regions.

Priced at just ₹6.70 lakh, significantly lower than imported alternatives, the RENALYX – RxT 21 is designed to address India’s growing chronic kidney disease (CKD) and end-stage renal disease (ESRD) burden.

Also Read: ChinniKrishnan Innovation Awards 2025 Now Open for Nominations from Startups and MSMEs

Built entirely in India, the machine is also the first of its kind in the country to earn EU CE certification, marking a significant global milestone for Indian medtech innovation.

Renalyx Health Systems: Pan-India and Global Expansion Plans

Renalyx Health Systems plans to invest ₹800 crore over four years to scale its manufacturing capabilities to 5,000 units annually by FY25-26 and an additional 1,500 units by FY27-28. With production facilities in Bengaluru, Mysuru, and Mumbai, Renalyx is targeting rapid domestic deployment and international expansion, having already received orders from South Africa, the USA, and Europe.

Advanced AI & IoMT Features

The RENALYX – RxT 21 boasts cutting-edge features including:

  • AI-based algorithms for treatment optimization
  • Nephrology Information System (NIS) on the cloud
  • Electronic Medical Records (EMR) integration
  • Remote telemetry and diagnostics
  • Internet of Medical Things (IoMT) capabilities for real-time monitoring

These tools allow clinicians to access patient data and respond to critical changes remotely, ensuring continuity of care across geographies.

Also Read: RVCE and Ramaiah Students Win Unisys Innovation Program 2025 with Disruptive Innovations

Domestic and Global Manufacturing Alliances

In addition to developing a home-dialysis model, Renalyx has partnered with Bharat Electronics Ltd. (BEL) to manufacture 6,000 units of its RxT 17 model, a standard hemodialysis machine. The two-product strategy will allow Renalyx to serve both basic and advanced care segments, especially in primary health centers (PHCs), community health centers (CHCs), and rural hospitals.

Next Steps

  • CDSCO approval expected by July 2025
  • US FDA approval anticipated by March 2026
  • Plans to go public within three years
  • Franchise and training infrastructure to support national scale-up

“The launch of RxT 21 is a giant leap in making dialysis affordable and accessible across India,” said Dr Shyam Vasudeva Rao, Founder & Director, Renalyx Health Systems. “With our AI-powered systems, we are reducing dialysis costs by up to 40% and expanding access to world-class treatment. This is aligned with the government’s ‘Make in India, Make for the World’ vision.”

Meeting India’s Growing Demand for Dialysis

According to the Pradhan Mantri National Dialysis Program (PMNDP), India witnesses approximately 2.2 lakh new ESRD cases annually, leading to a requirement for over 3.4 crore dialysis sessions each year. Renalyx’s innovation directly addresses this gap through indigenous innovation, cost efficiency, and scalable deployment.

Author

  • Salil Urunkar

    Salil Urunkar is a senior journalist and the editorial mind behind Sahyadri Startups. With years of experience covering Pune’s entrepreneurial rise, he’s passionate about telling the real stories of founders, disruptors, and game-changers.

Back to top